Nicola P Klein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8032141/publications.pdf

Version: 2024-02-01

140 papers	7,021 citations	70961 41 h-index	64668 79 g-index
141 all docs	141 docs citations	141 times ranked	5871 citing authors

#	Article	IF	Citations
1	Populationâ€based assessment of risks for severe COVIDâ€19 disease outcomes. Influenza and Other Respiratory Viruses, 2022, 16, 159-165.	1.5	20
2	Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness. Expert Review of Vaccines, 2022, 21, 899-907.	2.0	0
3	Safety of recombinant quadrivalent influenza vaccine compared to inactivated influenza vaccine in Chinese adults: An observational study. Vaccine, 2022, 40, 774-779.	1.7	0
4	Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine, 2022, 40, 2568-2573.	1.7	2
5	Adults hospitalized with breakthrough COVIDâ€19 have lower mortality than matched unvaccinated adults. Journal of Internal Medicine, 2022, 292, 377-384.	2.7	8
6	Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 Td (c 3, randomized trial. Vaccine, 2021, 39, 1534-1543.	1.7	2
7	Parental vaccine attitudes, beliefs, and practices: initial evidence in California after a vaccine policy change. Human Vaccines and Immunotherapeutics, 2021, 17, 1675-1680.	1.4	10
8	Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110212.	1.0	20
9	School-level perceptions and enforcement of the elimination of nonmedical exemptions to vaccination in California. Human Vaccines and Immunotherapeutics, 2021, 17, 1986-1993.	1.4	2
10	Studying attitudes towards vaccine hesitance and California law SB 277 in online discourse: A dataset and methodology. Data in Brief, 2021, 35, 106841.	0.5	0
11	Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine, 2021, 39, 3614-3620.	1.7	5
12	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 239-250.	13.9	709
13	Temporal Trends in Undervaccination: A Population-Based Cohort Study. American Journal of Preventive Medicine, 2021, 61, 64-72.	1.6	9
14	Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA - Journal of the American Medical Association, 2021, 326, 1390.	3.8	442
15	A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine, 2021, 39, 5428-5435.	1.7	36
16	Genetic associations with a fever after measles-containing vaccines. Human Vaccines and Immunotherapeutics, 2021, 17, 1763-1769.	1.4	5
17	A multi-country investigation of influenza vaccine coverage in pregnant individuals, 2010â€“2016. Vaccine, 2021, , .	1.7	3
18	Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 194-201.	0.6	10

#	Article	IF	Citations
19	Parental risk factors for fever in their children 7â€“10 days after the first dose of measles-containing vaccines. Human Vaccines and Immunotherapeutics, 2020, 16, 875-880.	1.4	3
20	If Influenza Vaccines Wane, Can We Delay Vaccination Without Compromising Coverage?. Clinical Infectious Diseases, 2020, 70, 1560-1561.	2.9	4
21	Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza Vaccine Effectiveness. Clinical Infectious Diseases, 2020, 70, 1484-1486.	2.9	26
22	Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010â€“2016. Journal of Infectious Diseases, 2020, 221, 1703-1712.	1.9	11
23	Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. Journal of Immunology, 2020, 205, 877-882.	0.4	17
24	Individual and Neighborhood Factors Associated With Failure to Vaccinate Against Influenza During Pregnancy. American Journal of Epidemiology, 2020, 189, 1379-1388.	1.6	9
25	Shouting at each other into the void: A linguistic network analysis of vaccine hesitance and support in online discourse regarding California law SB277. Social Science and Medicine, 2020, 266, 113216.	1.8	10
26	Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time. Human Vaccines and Immunotherapeutics, 2020, 16, 3098-3102.	1.4	1
27	Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study. Open Forum Infectious Diseases, 2020, 7, ofaa179.	0.4	3
28	Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS ONE, 2020, 15, e0229279.	1.1	34
29	Survey of influenza vaccine knowledge, attitudes, and beliefs among pregnant women in the 2016â€“17 season. Vaccine, 2020, 38, 2202-2208.	1.7	14
30	Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children. Human Vaccines and Immunotherapeutics, 2020, 16, 1753-1761.	1.4	1
31	Homeschooling parents in California: Attitudes, beliefs and behaviors associated with childâ€™s vaccination status. Vaccine, 2020, 38, 1899-1905.	1.7	7
32	Assessment of Exemptions From Vaccination in California, 2015 to 2027. Annals of Internal Medicine, 2020, 172, 362.	2.0	5
33	Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus. Vaccine, 2019, 37, 195-201.	1.7	20
34	Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine, 2019, 37, 5422-5427.	1.7	22
35	Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine, 2019, 37, 4460-4467.	1.7	3
36	Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012â€“13, 2013â€“14, and 2014â€“15. Vaccine, 2019, 37, 6673-6681.	1.7	39

#	Article	IF	Citations
37	Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics, 2019, 144, e20183466.	1.0	38
38	Elimination of Nonmedical Immunization Exemptions in California and School-Entry Vaccine Status. Pediatrics, 2019, 143, .	1.0	60
39	Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine, 2019, 37, 3296-3302.	1.7	4
40	Long term risk of developing type 1 diabetes after HPV vaccination in males and females. Vaccine, 2019, 37, 1938-1944.	1.7	10
41	Reply to Skowronski, De Serres, and Orenstein. Clinical Infectious Diseases, 2019, 69, 1085-1086.	2.9	2
42	Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics, 2019, 144, .	1.0	30
43	Electronic Medical Record Intervention to Improve Adherence to Prenatal Vaccination Recommendation [12F]. Obstetrics and Gynecology, 2019, 133, 65S-65S.	1.2	1
44	Intraseason Waning of Influenza Vaccine Effectiveness. Clinical Infectious Diseases, 2019, 68, 1623-1630.	2.9	75
45	Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Human Vaccines and Immunotherapeutics, 2019, 15, 809-821.	1.4	15
46	Exploring Californiaâ€™s new law eliminating personal belief exemptions to childhood vaccines and vaccine decision-making among homeschooling mothers in California. Vaccine, 2019, 37, 742-750.	1.7	18
47	Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. Vaccine, 2019, 37, 76-79.	1.7	6
48	Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study, 2010â€“2016. Clinical Infectious Diseases, 2019, 68, 1444-1453.	2.9	126
49	Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants. Human Vaccines and Immunotherapeutics, 2019, 15, 327-338.	1.4	3
50	Estimating Vaccine Effectiveness Against Hospitalized Influenza During Pregnancy: Multicountry Protocol for a Retrospective Cohort Study. JMIR Research Protocols, 2019, 8, e11333.	0.5	10
51	Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics, 2018, 141, e20173310.	1.0	41
52	Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine, 2018, 36, 2356-2363.	1.7	11
53	Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule. Academic Pediatrics, 2018, 18, 754-762.	1.0	11
54	Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. American Journal of Epidemiology, 2018, 187, 161-169.	1.6	70

#	Article	IF	Citations
55	Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine. Human Vaccines and Immunotherapeutics, 2018, 14, 412-419.	1.4	7
56	Comment on â€œThe impact of past vaccination coverage and immunity on pertussis resurgenceâ€. Science Translational Medicine, 2018, 10, .	5.8	6
57	A framework for research on vaccine effectiveness. Vaccine, 2018, 36, 7286-7293.	1.7	30
58	Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. Pharmacoepidemiology and Drug Safety, 2018, 27, 921-925.	0.9	7
59	Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy. Obstetrics and Gynecology, 2018, 132, 35-44.	1.2	27
60	The safety of live attenuated influenza vaccine in children and adolescents 2 through 17Âyears of age: A Vaccine Safety Datalink study. Pharmacoepidemiology and Drug Safety, 2018, 27, 59-68.	0.9	8
61	Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine, 2017, 35, 2668-2675.	1.7	15
62	Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine, 2017, 35, 3395-3400.	1.7	44
63	Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine, 2017, 35, 3564-3574.	1.7	2
64	First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring. Journal of Pediatrics, 2017, 187, 234-239.e4.	0.9	42
65	Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics, 2017, 139, .	1.0	187
66	Risk factors and familial clustering for fever 7â€“10 days after the first dose of measles vaccines. Vaccine, 2017, 35, 1615-1621.	1.7	9
67	Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. Vaccine, 2017, 35, 1873-1878.	1.7	15
68	Use of acellular pertussis vaccines in the United States: can we do better?. Expert Review of Vaccines, 2017, 16, 1175-1179.	2.0	8
69	Patterns of childhood immunization and all-cause mortality. Vaccine, 2017, 35, 6643-6648.	1.7	2
70	Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. Pediatric Neurology, 2017, 76, 72-78.	1.0	19
71	Risk of venous thromboembolism following influenza vaccination in adults aged 50 years and older in the Vaccine Safety Datalink. Vaccine, 2017, 35, 5872-5877.	1.7	15
72	Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010â€“11 and 2011â€“12. Vaccine, 2017, 35, 5314-5322.	1.7	79

#	Article	IF	Citations
73	Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Pediatric Infectious Disease Journal, 2016, 35, 662-672.	1.1	16
74	Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine, 2016, 34, 4172-4179.	1.7	23
75	Influenza Vaccination During Pregnancy. American Journal of Preventive Medicine, 2016, 50, 480-488.	1.6	31
76	Suddenâ€Onset Sensorineural Hearing Loss after Immunization. Otolaryngology - Head and Neck Surgery, 2016, 155, 81-86.	1.1	30
77	Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics, 2016, 138, .	1.0	59
78	Waning Tdap Effectiveness in Adolescents. Pediatrics, 2016, 137, e20153326.	1.0	111
79	Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007â€“2013. Vaccine, 2016, 34, 968-973.	1.7	100
80	Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008â€“2011. Vaccine, 2016, 34, 167-171.	1.7	18
81	An Overview of Quadrivalent Human Papillomavirus Vaccine Safety. Pediatric Infectious Disease Journal, 2015, 34, 983-991.	1.1	103
82	Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstetrics and Gynecology, 2015, 126, 1069-1074.	1.2	86
83	Safety of Measles-Containing Vaccines in 1-Year-Old Children. Pediatrics, 2015, 135, e321-e329.	1.0	38
84	Differentiating Sepsis From Adverse Events After Immunization in the Neonatal Intensive Care Unit. JAMA Pediatrics, 2015, 169, 718.	3.3	1
85	Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA - Journal of the American Medical Association, 2015, 314, 1581.	3.8	91
86	Evaluation of the Association of Maternal Pertussis Vaccination With Obstetric Events and Birth Outcomes. JAMA - Journal of the American Medical Association, 2014, 312, 1897.	3.8	177
87	Licensed pertussis vaccines in the United States. Human Vaccines and Immunotherapeutics, 2014, 10, 2684-2690.	1.4	57
88	Risk of Intussusception after Monovalent Rotavirus Vaccination. New England Journal of Medicine, 2014, 370, 513-519.	13.9	201
89	Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaPâ€IPV) vaccine. Vaccine, 2014, 32, 3019-3024.	1.7	36
90	The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine, 2014, 32, 5390-5398.	1.7	175

#	Article	IF	Citations
91	Timely Versus Delayed Early Childhood Vaccination and Seizures. Pediatrics, 2014, 133, e1492-e1499.	1.0	45
92	Factors that may explain observed associations between trivalent influenza vaccination and gastrointestinal illness in young children. Vaccine, 2013, 31, 3894-3898.	1.7	0
93	Comprehensive Assessment of Serious Adverse Events Following Immunization by Health Care Providers. Journal of Pediatrics, 2013, 162, 1276-1281.e1.	0.9	9
94	Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ, The, 2013, 347, f4249-f4249.	3.0	68
95	Lack of Association of Guillain-Barre Syndrome With Vaccinations. Clinical Infectious Diseases, 2013, 57, 197-204.	2.9	96
96	Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety Study. American Journal of Epidemiology, 2013, 177, 131-141.	1.6	39
97	Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers. Pediatrics, 2013, 131, e1716-e1722.	1.0	163
98	Effect of Age on the Risk of Fever and Seizures Following Immunization With Measles-Containing Vaccines in Children. JAMA Pediatrics, 2013, 167, 1111.	3.3	65
99	Incidence of Genital Warts in Adolescents and Young Adults in an Integrated Health Care Delivery System in the United States Before Human Papillomavirus Vaccine Recommendations. Sexually Transmitted Diseases, 2013, 40, 534-538.	0.8	18
100	One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children. Pediatric Infectious Disease Journal, 2013, 32, 760-767.	1.1	36
101	Long-term Immune Responses to Pneumococcal Conjugate Vaccines in Children Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2013, 32, 990-997.	1.1	4
102	Kaiser Permanente Vaccine Study Center: Highlights of 2009â€“2012. Vaccines, 2013, 1, 139-153.	2.1	0
103	Epidemiologic and Clinical Features of Bellâ€™s Palsy among Children in Northern California. Neuroepidemiology, 2012, 38, 252-258.	1.1	43
104	Recurrent Guillain-Barre Syndrome Following Vaccination. Clinical Infectious Diseases, 2012, 54, 800-804.	2.9	45
105	Immunization and Bell's Palsy in Children: A Case-Centered Analysis. American Journal of Epidemiology, 2012, 175, 878-885.	1.6	49
106	Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children. New England Journal of Medicine, 2012, 367, 1012-1019.	13.9	471
107	Safety of Quadrivalent Human Papillomavirus Vaccine Administered Routinely to Females. JAMA Pediatrics, 2012, 166, 1140.	3.6	104
108	Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants. Pediatric Infectious Disease Journal, 2012, 31, 64-71.	1.1	55

#	Article	IF	Citations
109	Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age. Pediatric Infectious Disease Journal, 2012, 31, e133-e140.	1.1	23
110	Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine, 2012, 31, 271-277.	1.7	46
111	Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years. Pediatrics, 2012, 129, 809-814.	1.0	44
112	An open-label, randomized, multi-center study of the immunogenicity and safety of DTaPâ€“IPV (Kinrixâ„¢) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine, 2012, 30, 668-674.	1.7	13
113	Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: A randomized, controlled, open-label, multicenter study. Vaccine, 2012, 30, 3360-3368.	1.7	8
114	Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine, 2012, 30, 3929-3936.	1.7	32
115	Algorithm to assess causality after individual adverse events following immunizations. Vaccine, 2012, 30, 5791-5798.	1.7	61
116	An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine, 2012, 30, 4585-4587.	1.7	16
117	Developing the next generation of vaccinologists. Vaccine, 2011, 29, 9296-9297.	1.7	2
118	Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15â€“59 years of age. Vaccine, 2011, 29, 6592-6597.	1.7	41
119	Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004â€“2009. Vaccine, 2011, 29, 6920-6927.	1.7	31
120	Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink. Vaccine, 2011, 29, 8279-8284.	1.7	195
121	Safety of Trivalent Inactivated Influenza Vaccine in Children Aged 24 to 59 Months in the Vaccine Safety Datalink. JAMA Pediatrics, 2011, 165, 749.	3.6	37
122	Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine When Coadministered With Diphtheria-tetanus-acellular Pertussis and Haemophilus influenzae Type B Vaccines in Children 15 Months of Age. Pediatric Infectious Disease Journal, 2011, 30, e164-e169.	1.1	3
123	Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project. Pediatrics, 2011, 127, S54-S64.	1.0	110
124	Attitudes and Beliefs of Parents Concerned About Vaccines: Impact of Timing of Immunization Information. Pediatrics, 2011, 127, S120-S126.	1.0	79
125	The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety. Pediatrics, 2011, 127, S45-S53.	1.0	247
126	Understanding the Role of Human Variation in Vaccine Adverse Events: The Clinical Immunization Safety Assessment Network. Pediatrics, 2011, 127, S65-S73.	1.0	40

#	Article	IF	Citations
127	Vaccine safety in special populations. Hum Vaccin, 2011, 7, 269-271.	2.4	3
128	Evaluation of Immunization Rates and Safety Among Children With Inborn Errors of Metabolism. Pediatrics, 2011, 127, e1139-e1146.	1.0	38
129	Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance Organization. Pediatric Infectious Disease Journal, 2010, 29, 613-617.	1.1	33
130	Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures. Pediatrics, 2010, 126, e1-e8.	1.0	290
131	Preterm Infants' T Cell Responses to Inactivated Poliovirus Vaccine. Journal of Infectious Diseases, 2010, 201, 214-222.	1.9	22
132	Lack of Association Between Acellular Pertussis Vaccine and Seizures in Early Childhood. Pediatrics, 2010, 126, 263-269.	1.0	55
133	Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine, 2010, 28, 1062-1068.	1.7	108
134	Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2â€“10 years of age. Vaccine, 2010, 28, 7865-7872.	1.7	54
135	Differential maternal responses to a newly developed vaccine information pamphlet. Vaccine, 2009, 28, 323-328.	1.7	21
136	Recurrent sterile abscesses following aluminium adjuvant-containing vaccines. BMJ Case Reports, 2009, 2009, bcr0920080951-bcr0920080951.	0.2	16
137	Kinrixâ„¢: a new combination DTaPâ€“IPV vaccine for children aged 4â€“6 years. Expert Review of Vaccines, 2008, 7, 1309-1320.	2.0	10
138	Risk Factors for Developing Apnea After Immunization in the Neonatal Intensive Care Unit. Pediatrics, 2008, 121, 463-469.	1.0	66
139	Diphtheria-Tetanus-Acellular Pertussis and Inactivated Poliovirus Vaccines Given Separately or Combined for Booster Dosing at 4â€“6 Years of Age. Pediatric Infectious Disease Journal, 2008, 27, 341-346.	1.1	19
140	A Role for Genetics in the Immune Response to the Varicella Vaccine. Pediatric Infectious Disease Journal, 2007, 26, 300-305.	1.1	30